ABSTRACT
Long non-coding RNA (lncRNA) can affect the occurrence and development of diseases by directly or indirectly regulating target genes and their signal pathways. With the deepening of research, more and more lncRNA have been found to be involved in regulating the occurrence, development and drug resistance of multiple myeloma (MM). Therefore, it is necessary to study the role and molecular mechanism of abnormal expression of lncRNA in MM, which can provide theoretical basis for clinical diagnosis and targeted therapy.
Subject(s)
Multiple Myeloma , RNA, Long Noncoding , Humans , Multiple Myeloma/diagnosis , Multiple Myeloma/drug therapy , Multiple Myeloma/genetics , Multiple Myeloma/therapy , RNA, Long Noncoding/genetics , RNA, Long Noncoding/metabolism , Signal TransductionABSTRACT
Long non-coding RNA (lncRNA) is not "transcriptional noise". It can regulate gene expression at pre-transcriptional, post-transcriptional and epigenetic level and participate in the occurrence and development of diseases. A large number of studies have shown that the abnormal expression of lncRNA plays an important role in the occurrence and development of acute myeloid leukemia (AML) and drug resistance. LncRNA can participate in the occurrence, development and drug resistance of AML by acting on target genes and regulating related signal pathways. Detection of its expression has a certain prognostic value. Therefore, this article briefly discusses the research progress of lncRNA in AML, hoping to provide ideas for clinical diagnosis and targeted therapy.
